Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 10:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 14,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Obese, Obesity, Obesity Type 2 Diabetes Mellitus, Weight Loss
Interventions: Aleniglipron, Placebo; Drug
Lead sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 16
States / cities: Anniston, Alabama • Lake Forest, California • Lomita, California + 11 more

Conditions: Obsessive Compulsive Disorder
Interventions: Active DTMS Treatment, Sham Treatment; Device
Lead sponsor: Brainsway; Industry
Eligibility: 22 Years to 68 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 10
States / cities: Los Angeles, California • San Diego, California • Gainesville, Florida + 5 more

Conditions: Cataract, Glaucoma, Ocular Hypertension
Interventions: Bimatoprost Implant System, SpyGlass IOL, Timolol Maleate Ophthalmic Solution, 0.5%, Commercial IOL; Drug · Device
Lead sponsor: SpyGlass Pharma, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Avian Influenza
Interventions: MF59, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 65 Years to 99 Years
Enrollment: 479 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: Decatur, Georgia • Iowa City, Iowa • Baltimore, Maryland + 7 more

Conditions: Primary Four Repeat Tauopathies (4RT), Corticobasal Syndrome (CBS), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
Interventions: TPI 287 2 mg/m2, TPI-287 20 mg/m2, Placebo, TPI-287 6.3 mg/m2; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 50 Years to 85 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: Birmingham, Alabama • San Francisco, California

Conditions: HIV Infection
Interventions: Vitamin D3 50,000 IU, Vitamin D3 placebo; Dietary Supplement
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 16 Years to 24 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 16
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 11 more

Conditions: Rheumatoid Arthritis
Interventions: LY2127399, Placebo Q4W, Placebo Q2W; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 110
States / cities: Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 107 more

Conditions: Diabetes
Interventions: Switching to NPH insulin, Continuation of insulin glargine; Drug
Lead sponsor: Providence Health & Services; Other
Eligibility: Up to 85 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Geographic Atrophy
Interventions: Sham, Lampalizumab; Other · Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 36
States / cities: Mesa, Arizona • Tucson, Arizona • Springdale, Arkansas + 33 more

Conditions: Atopic Dermatitis
Interventions: Tapinarof cream, 1%, Vehicle Cream; Drug
Lead sponsor: Organon and Co; Industry
Eligibility: 3 Months to 23 Months
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 36
States / cities: Birmingham, Alabama • Bryant, Arkansas • Los Angeles, California + 32 more

Conditions: Delirium, Agitation
Interventions: Risperidone, Trazodone, Placebo; Drug
Lead sponsor: Rochester General Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Postpartum Depression, Parenting, Parent-Child Relations, Child Development
Interventions: MoodGym, Social Media-Based Parenting Program; Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 18 Years and older · Female only
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: COPD Acute Exacerbation
Interventions: Rademikibart in prefilled syringe, Matching placebo in prefilled syringe; Combination Product · Drug
Lead sponsor: Connect Biopharm LLC; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 21
States / cities: Birmingham, Alabama • Palo Alto, California • Valencia, California + 17 more

Conditions: Knee Osteoarthritis
Interventions: Lorecivivint, Placebo; Drug
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 44
States / cities: Tucson, Arizona • Cerritos, California • La Mesa, California + 35 more

Conditions: Bunionectomy, Pain, Postoperative Pain, Acute Pain
Interventions: CG5503 IR, Morphine, Placebo; Drug
Lead sponsor: Grünenthal GmbH; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 6
States / cities: Pasadena, Maryland • Austin, Texas • Houston, Texas + 3 more

Conditions: Influenza
Interventions: 2 mg/kg CR8020, 5 mg/kg CR8020, 15 mg/kg CR8020, 30 mg/kg CR8020, 50 mg/kg CR8020, Placebo; Biological
Lead sponsor: Crucell Holland BV; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Urothelial Carcinoma, Bladder Cancer
Interventions: Atezolizumab, Enfortumab Vedotin, Niraparib, Magrolimab (Hu5F9-G4), Tiragolumab, Sacituzumab Govitecan, Tocilizumab, Cisplatin, Gemcitabine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 10
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 6 more

Conditions: Asthma
Interventions: Fexofenadine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Hypertension, Uncontrolled Hypertension
Interventions: iloperidone, Placebo; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 28
States / cities: Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 25 more

Conditions: Preeclampsia
Interventions: Pravastatin, Placebo; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 3
States / cities: Chicago, Illinois • Pittsburgh, Pennsylvania • Galveston, Texas

Conditions: COVID-19, Lung Inflammation
Interventions: Regadenoson, Placebo Control; Drug · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Alcohol Use Disorder (AUD)
Interventions: Pemvidutide, Placebo; Drug · Other
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 12
States / cities: Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 9 more

Conditions: Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions: Ravulizumab; Biological
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 10
States / cities: Aurora, Colorado • Fort Collins, Colorado • Washington D.C., District of Columbia + 7 more

Conditions: Acute Pain
Interventions: Suzetrigine (SUZ), HB/APAP, Placebo (matched to SUZ), Placebo (matched to HB/APAP); Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 12
States / cities: Sheffield, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 8 more

Search by objective public record fields.

Aleniglipron Phase 2 in Type 2 Diabetes Mellitus

An Evaluation of the Safety and Efficacy of the dTMS Treatment for OCD

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)

H7N9 Mix and Match With MF59 in Healthy Elderly Persons

Safety Study of TPI-287 to Treat CBS and PSP

Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART

A Study in Participants With Rheumatoid Arthritis

Comparison Study of Insulin Glargine and NPH Insulin

A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy

A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

Efficacy and Safety of Risperidone and Trazodone Monotherapy and Combination Therapy in Critically Ill Patients With Delirium

Social Media-Based Parenting Program for Women With Postpartum Depressive Symptoms: Impact on Child Development

Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)

Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Knee Osteoarthritis (STRIDES)

A Trial to Evaluate CG5503 Efficacy and Safety in Acute Pain After Bunionectomy

Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma

Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension

Pravastatin for Prevention of Preeclampsia

Treat COVID-19 Patients With Regadenoson

RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight

An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD

Evaluation of Efficacy and Safety of Suzetrigine for Acute Pain After an Abdominoplasty